Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedMar 26, 2026
DataAggregated Company Financials
Companies5
  • 7D0.2%
  • 3M-23.1%
  • 1Y3.0%
  • YTD-19.3%

The Biotech industry has stayed flat over the last week. In line with that, the industry has also been flat over the past 12 months. Looking forward, earnings are forecast to grow by 1.7% annually.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 26 Mar 2026DKK 138.1bDKK 39.5bDKK 14.0b10.7x9.9x3.5x
Sat, 21 Feb 2026DKK 157.7bDKK 39.7bDKK 14.9b6.3x10.6x4x
Mon, 19 Jan 2026DKK 180.3bDKK 40.8bDKK 19.1b6.4x9.4x4.4x
Wed, 17 Dec 2025DKK 170.3bDKK 40.5bDKK 18.9b5.9x9x4.2x
Fri, 14 Nov 2025DKK 172.8bDKK 40.3bDKK 18.2b10.3x9.5x4.3x
Sun, 12 Oct 2025DKK 179.8bDKK 39.1bDKK 16.8b12.9x10.7x4.6x
Tue, 09 Sep 2025DKK 157.7bDKK 38.8bDKK 16.7b12.3x9.4x4.1x
Thu, 07 Aug 2025DKK 125.8bDKK 27.0bDKK 7.3b12.8x17.1x4.7x
Sat, 05 Jul 2025DKK 120.7bDKK 26.8bDKK 7.3b10.6x16.6x4.5x
Mon, 02 Jun 2025DKK 131.2bDKK 27.5bDKK 7.5b10.8x17.4x4.8x
Wed, 30 Apr 2025DKK 130.4bDKK 27.3bDKK 7.7b11.6x17x4.8x
Fri, 28 Mar 2025DKK 139.5bDKK 27.3bDKK 7.7b11.9x18.2x5.1x
Sun, 23 Feb 2025DKK 165.3bDKK 27.7bDKK 7.8b12.5x21.2x6x
Tue, 21 Jan 2025DKK 161.1bDKK 26.0bDKK 4.7b17x34.3x6.2x
Thu, 19 Dec 2024DKK 167.5bDKK 26.0bDKK 4.7b17x35.7x6.4x
Sat, 16 Nov 2024DKK 157.0bDKK 26.0bDKK 4.3b19.2x36.6x6x
Mon, 14 Oct 2024DKK 173.8bDKK 25.5bDKK 5.5b20.9x31.8x6.8x
Wed, 11 Sep 2024DKK 197.1bDKK 25.5bDKK 5.5b23.4x36x7.7x
Fri, 09 Aug 2024DKK 193.3bDKK 24.8bDKK 5.6b18.1x34.3x7.8x
Sun, 07 Jul 2024DKK 193.1bDKK 24.8bDKK 5.6b17.2x34.3x7.8x
Tue, 04 Jun 2024DKK 181.9bDKK 24.8bDKK 5.6b18.9x32.3x7.3x
Thu, 02 May 2024DKK 178.7bDKK 23.9bDKK 5.0b18.6x35.5x7.5x
Sat, 30 Mar 2024DKK 190.9bDKK 23.9bDKK 5.0b19.7x38x8x
Mon, 26 Feb 2024DKK 175.5bDKK 22.8bDKK 4.2b24.6x41.6x7.7x
Wed, 24 Jan 2024DKK 165.4bDKK 23.3bDKK 4.2b23.1x39.7x7.1x
Fri, 22 Dec 2023DKK 173.0bDKK 23.3bDKK 4.2b25.1x41.6x7.4x
Sun, 19 Nov 2023DKK 174.6bDKK 23.3bDKK 4.2b24.6x41.9x7.5x
Tue, 17 Oct 2023DKK 176.7bDKK 22.0bDKK 4.7b20.3x37.3x8x
Thu, 14 Sep 2023DKK 194.2bDKK 22.0bDKK 4.7b22.5x41x8.8x
Sat, 12 Aug 2023DKK 193.6bDKK 20.6bDKK 3.9b38.5x50x9.4x
Mon, 10 Jul 2023DKK 196.9bDKK 19.5bDKK 4.4b39.4x44.7x10.1x
Wed, 07 Jun 2023DKK 210.1bDKK 19.5bDKK 4.4b43.1x47.7x10.7x
Fri, 05 May 2023DKK 205.8bDKK 17.9bDKK 4.1b32.3x50.3x11.5x
Sun, 02 Apr 2023DKK 197.4bDKK 17.9bDKK 3.5b30.6x55.8x11x
Price to Earnings Ratio

55.8x


Total Market Cap: DKK 197.4bTotal Earnings: DKK 3.5bTotal Revenue: DKK 17.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 29.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 9.9x which is lower than its 3-year average PE of 29.8x.
  • The 3-year average PS ratio of 6.8x is higher than the industry's current PS ratio of 3.5x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 58% per year over the last three years.
  • Revenues for these companies have grown 30% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-2.71%
Healthcare-2.29%
Biotech0.24%
Biotech0.24%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GMAB GenmabDKK 1.69k3.0%
+DKK 3.0b		21.1%PE16.7x
ZEAL Zealand PharmaDKK 291.704.3%
+DKK 847.4m		-45.3%PE3.2x
BAVA Bavarian NordicDKK 192.004.7%
+DKK 647.5m		21.8%PE10.8x

Latest News

BAVA
DKK 192.00
Bavarian Nordic
7D
4.7%
1Y
21.8%
ZEAL
DKK 291.70
Zealand Pharma
7D
4.3%
1Y
-45.3%

ZEAL: Obesity Trial Partnering With Roche Will Drive Future Re-Rating Potential

The analyst price target for Zealand Pharma has been revised lower to DKK 825 from DKK 1,120, reflecting recent reductions in Street targets and more cautious views on petrelintide's potential in a crowded obesity market, even as analysts still model healthier margins and a lower future P/E multiple. Analyst Commentary Recent Street research reflects a reset in expectations for Zealand Pharma, with multiple firms cutting price targets and moving to more neutral ratings after the Phase II ZUPREME-1 and Phase 2b petrelintide obesity data.
BIOPOR
DKK 0.86
BioPorto
7D
-7.2%
1Y
-38.0%
GMAB
DKK 1,694.50
Genmab
7D
3.0%
1Y
21.1%

GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead

Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.
STRAP
DKK 560.00
Strategic Partners
7D
-9.7%
1Y
-30.0%